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Background: Carotid artery stenting (CAS) is considered by many as an alternative to carotid endarterectomy (CEA) for
the management of carotid artery stenosis. However, recent trials demonstrated inferior results for CAS in symptomatic
patients compared with CEA. We reviewed the literature to evaluate the appropriateness of CAS for symptomatic carotid
artery stenosis and to determine the pathogenetic mechanism(s) associated with stroke following the treatment of such
lesions. Based on this, we propose steps to improve the results of CAS for the treatment of symptomatic carotid stenosis.
Methods: PubMed/Medline was searched up to March 25, 2010 for studies investigating the efficacy of CAS for the
management of symptomatic carotid stenosis. Search terms used were “carotid artery stenting,” “symptomatic carotid
artery stenosis,” “carotid endarterectomy,” “stroke,” “recurrent carotid stenosis,” and “long-term results” in various
combinations.
Results: Current data suggest that CAS is not equivalent to CEA for the treatment of symptomatic carotid stenosis.
Differences in carotid plaque morphology and a higher incidence of microemboli and cerebrovascular events during and
after CAS compared with CEA may account for these inferior results.
Conclusions: Currently, most symptomatic patients are inappropriate candidates for CAS. Improved CAS technology
referable to stent design and embolic protection strategies may alter this conclusion in the future. ( J Vasc Surg 2010;52:
1367-75.)Carotid artery stenting (CAS) has emerged as an alter-
native to carotid endarterectomy (CEA) for the manage-
ment of carotid artery stenosis.1-4 Large, multicenter stud-
ies have shown that CAS is not inferior to CEA for the
management of carotid artery stenosis in some largely
asymptomatic patient groups.3,4 This led the supporters of
CAS to dispute CEA as the “gold standard” treatment for
carotid artery stenosis.1,4
Although CAS may provide similar results to CEA for
asymptomatic carotid artery stenosis,3,4 this may not be
true for symptomatic patients. The mechanisms associated
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stenosis may involve an entirely different process in terms of
lesion behavior and natural history compared with those of
asymptomatic carotid artery disease. Because of these dif-
ferences, several possible options to improve CAS out-
comes may exist in symptomatic patients. The purpose of
this article is to review the relevant literature and discuss
these options.
MATERIALS AND METHODS
PubMed/Medline was searched up to March 25, 2010
for studies evaluating the efficacy of CAS compared with
CEA in symptomatic carotid artery stenosis. Search terms
were “carotid artery stenting,” “symptomatic carotid artery
stenosis,” “carotid endarterectomy,” “stroke,” “recurrent
carotid stenosis,” and “long-term results” in various com-
binations. The reference lists of the gathered reports were
also manually searched.
RESULTS
Several studies comparing the efficacy of CAS with
CEA were identified (Table).3,5-20 The majority of these
trials showed that the presence of neurological symp-
toms prior to CAS was independently associated with
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November 20101368 Paraskevas et alTable. Neurological complications after CAS and CEA for symptomatic carotid artery stenosis
Study (year) Study design Study outcome
Leicester study5
(1998)
Randomization of symptomatic pts
with 70% carotid stenosis to
CEA (n  10) or CAS (n  13)
- Incidence of stroke: 0 of 10 CEAs vs 5 of 7 CAS procedures; P  .0034
- The Data Monitoring Committee stopped this trial prematurely due to
the unacceptable high stroke rate following CAS.
Qureshi et al6
(2000)
Comparison of the angiograms of
111 pts undergoing CAS for
asymptomatic (n  54) or
symptomatic (n  57) carotid
artery stenosis
- The presence of neurological symptoms prior to CAS was independently
associated with a 8-fold risk of the development of periprocedural
neurological deficits (OR, 8.3; 95% CI, 1.6-42.6; P  .01).
Golledge et al7
(2000)
Systematic comparison of the
30-day outcome of 13 studies of
angioplasty with/without
stenting and 20 CEA studies for
the management of symptomatic
carotid artery disease.
- Any stroke: 51 of 714 vs 233 of 6970, for angioplasty vs CEA,
respectively; OR, 2.22; 95% CI, 1.62-3.04; 226.5; P  .0001.
- Disabling or fatal stroke: 23 of 714 vs 78 of 4973 for angioplasty vs
CEA, respectively; OR, 2.09; 95% CI, 1.3-3.33; 28.8; P  .01.
- Incidence of combined stroke and death: 56 of 714 vs 201 of 4973, or
7.8% vs 4%, after angioplasty vs CEA, respectively; OR, 2.02; 95% CI,
1.49-2.75; 2  20.6; P  .001).
Kentucky
study8
(2001)
Randomization of symptomatic pts
with a 70% carotid stenosis to
CAS (n  53) or CEA (n  51).
- No strokes in pts undergoing either CAS or CEA.
- One individual died of an MI immediately after CEA.
WALLSTENT9
(2001)
Randomization of 219
symptomatic pts with 60%
carotid stenosis to CAS
(n  107) or CEA (n  112).
- 30-day periprocedural complication (any stroke or death) rate: 12.1% vs
4.5%, for CAS vs CEA, respectively; P  .049.
ICAROS10
(2004)
Correlation of a highly
reproducible index of carotid
plaque echogenicity, the GSM,
with the risk of stroke after CAS.
- Incidence of stroke after CAS: 7.1  2.1% vs 1.5  0.8%, for GSM 25
vs GSM 25, respectively; P  .005.
- Independent predictors of stroke after CAS: i) GSM 25 (OR, 7.11;
95% CI, 2.06-24.57; P  .002) and, ii) 85% stenosis (OR, 5.76; 95%
CI, 1.51-21.91; P  .010).
Kastrup et al11
(2005)
Comparison of complication rates
in 129 asymptomatic with 170
symptomatic pts with carotid
artery stenosis (70% for
symptomatic; 90% for
asymptomatic pts) undergoing
CAS.
- Incidence of TIA, stroke, and death: 15.3% vs 3.1%, for symptomatic vs
asymptomatic pts, respectively; P  .01).
- A previous hemispherical TIA prior to CAS was associated with an
almost 5-fold higher risk (OR, 4.7; 95% CI, 1.6-13.3; P  .004) for the
development of postprocedural TIA, minor/major stroke and death.
- A history of stroke prior to CAS was associated with an 8-fold higher
risk (OR, 8.0; 95% CI, 2.6-24.4; P  .001) for the development of
postprocedural TIA, minor/major stroke, and death.
CAVATAS12
(2005)
Randomization of 504 pts with
carotid artery stenosis to
endovascular treatmenta or CEA
(251 vs 253 pts, respectively).
- Rate of death/disabling stroke in any vascular territory/ipsilateral stroke
rate: 14.3% vs 14.2% for endovascular treatment vs CEA, respectively.
- Severe (70%-99%) recurrent carotid stenosis on ultrasound at 1 year: 25
vs 7 pts, or 14% vs 4%, for endovascular treatment vs CEA, respectively,
P  .001.
- Severe stenosis or occlusion at 1 year in the subgroup of pts treated by
stenting:a 9 of 41 pts (22%).
SPACE13
(2006)
Randomization of pts with 70%
symptomatic carotid stenosis to
CAS (n  613) or CEA
(n  601).
- 30-day death or ipsilateral ischemic stroke rates: 6.84% vs 6.34%, for
CAS vs CEA, respectively; absolute difference, 0.51%; 90% CI, 1.89%
to 2.91%; P  .09.
EVA-3S14
(2006)
Comparison of CAS (n  265) vs
CEA (n  262) for symptomatic
carotid artery stenosis 60%.
- Incidence of nonfatal stroke: 8.8% vs 2.7%, for CAS vs CEA,
respectively; RR, 3.3; 95% CI, 1.4-7.5; P  .004.
- Incidence of 30-day stroke or death: 9.6% vs 3.9%, for CAS vs CEA,
respectively; RR, 2.5; 95% CI, 1.2-5.1; P  .01.
- Incidence of any stroke or death at 6 months: 11.7% vs 6.1%, for CAS
vs CEA, respectively; P  .02.
Pro-CAS15
(2008)
Multicenter (n  25) prospective
analysis of possible predictors of
death and stroke after CAS
procedures (n  5341)
- Periprocedural stroke or death: 4.3% vs 2.7% for symptomatic vs
asymptomatic carotid stenosis, respectively; P  .0019.
- The presence of symptoms was associated with a 1.5-fold increased
risk for the occurrence of stroke and/or death following CAS (OR,
1.54; 95% CI, 1.1-2.1; P  .008).
EVA-3S16
(2008)
4-year follow-up data of the
original EVA-3S study.14
- Incidence of 30-day stroke/death rate or nonprocedural ipsilateral
stroke: 6.2% vs 11.1%, for CEA vs CAS, respectively; HR, 1.97; 95% CI,
1.06-3.67; P  .03 for CAS vs CEA.
- Any stroke or periprocedural death: HR, 1.77; 95% CI, 1.03-3.02;
P  .04.- Any stroke or death: HR, 1.39; 95% CI, 0.96-2.00; P  .08.
treate
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events.5-7,9-11,14-16,18,20 Interpretation of these results
suggests that currently most symptomatic patients with a
history of transient ischemic attack (TIA) or stroke should
probably not be treated by CAS.
More recently, one single-center18 and two multi-
center16,17 randomized trials comparing the late results of
CAS with CEA for the management of symptomatic ca-
rotid artery stenosis indicated that CAS provides inferior
long-term results compared with CEA. A higher rate of
recurrent carotid stenosis17,18 or a higher incidence of
stroke/periprocedural death16 were the main drawbacks
for CAS compared with CEA. A detailed evaluation and
critical overview of the results of these trials is presented
elsewhere.21 This review also concluded that CAS is infe-
rior to CEA for symptomatic patients but noted that “the
results of soon-to-be reported trials (Carotid Revasculariza-
tion: Endarterectomy vs Stenting Trial [CREST], Inter-
national Carotid Stenting Study [ICSS], or others) may
alter the current impression that CAS is inferior to CEA for
Table. Continued
Study (year) Study design
SPACE17(2008) 2-year follow-up data of the
original SPACE study.13
- In
vs
- In
4.
Steinbauer et
al18 (2008)
Single-center randomized study
comparing the long-term (mean
follow-up: 66  14.2 vs
64  12.1 months, respectively)
results of CAS (n  43) with
CEA (n  44)
- Ip
- 
P
- Re
pt
CAVATAS19
(2009)
5-year results of the initial
CAVATAS Study.12
- In
fo
H
ICSS20 (2010) Randomization of 1710
symptomatic pts to CAS
(n  853) vs CEA (n  857)
- Ri
H
- Ri
H
- Ri
2.
- Ri
C
CREST3
(2010)
Randomization of 2,502 pts (1321
symptomatic; 1181
asymptomatic) to CAS
(n1262) or CEA (n1240).
- Pr

C
- Pe
P
- D
re
- M
P
CAS, Carotid artery stenting; CAVATAS, Carotid and Vertebral Artery T
interval; CREST, Carotid Revascularization: Endarterectomy versus Sten
Angioplasty in Pts with Symptomatic Severe Carotid Stenosis; GSM, gray
ICAROS, Imaging in Carotid Angioplasty and Risk of Stroke study; MI, my
stenting; TIA, transient ischemic attack; pts, patients; RR, relative risk; SPA
aFor endovascular patients treated successfully (n  213), stents were used
bThe risk of 70% recurrent stenosis at 5 years was lower in those patients
36.2%, respectively; adjusted HR, 0.43; 95% CI, 0.19-0.97; P  .04), butthe treatment of symptomatic carotid stenosis.”21ICSS recently reported its 120-day results after ran-
domization to CAS or CEA.20 Eligible patients undergoing
CAS (n 828) had a higher 120-day risk of any stroke (65
vs 35 events, or 7.7% vs 4.1%, respectively; hazard ratio
[HR], 1.92; 95% confidence interval [CI], 1.27-2.89; P 
.002), any stroke or death (72 vs 40 events, or 8.5% vs 4.7%,
respectively; HR, 1.86; 95% CI, 1.26-2.74; P  .0001),
all-cause death (19 vs 7 events, or 2.3% vs 0.8%, respec-
tively; HR, 2.76; 95% CI, 1.16-6.56; P  .017), as well as
any stroke, death, or procedural myocardial infarction (MI)
(72 vs 44 events, or 8.5% vs 5.9%, respectively; HR, 1.69;
95% CI, 1.16-2.45; P  .006) compared with individuals
undergoing CEA (n 821).20 Furthermore, in a substudy
where a magnetic resonance imaging (MRI) scan with
vascular sequences was carried out before the procedure,
followed by an early (1-3 days) and a late (27-33 days)
postprocedural scan, new ischemic lesions on diffusion-
weighted imaging were found in half of CAS vs 20% of
CEA patients (50% vs 17%, respectively; adjusted odds ratio
[OR], 5.21; 95% CI, 2.78-9.79; P  .0001).22 The con-
Study outcome
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more new ischemic lesions on diffusion-weighted imaging
compared with CEA.22 The final results of ICSS, which
include the 3-year rates of fatal or disabling stroke in any
territory after CAS and CEA, remain to be reported.
Recently, CREST also announced its results.3 A total of
2,502 patients were randomized to CAS (n  1,262) or
CEA (n  1,240). The primary endpoint of death, MI, or
stroke at 30 days plus ipsilateral stroke occurring30 days
following the procedure was similar between patients un-
dergoing CAS and CEA (7.2% vs 6.8%, respectively; HR,
1.11; 95% CI, 0.81-1.51; P  .51). Nevertheless, patients
undergoing CAS suffered more periprocedural strokes
(4.1% vs 2.3%, for CAS vs CEA, respectively; P  .01) and
more minor strokes (2.7% vs 1.5%, for CAS vs CEA, respec-
tively; P  .05) compared with individuals undergoing
CEA.3 In contrast with previous studies,5-7,9-11,14-16,18,20
there was no difference in the incidence of 30-day stroke
rates between the two groups based on the presence of
preprocedural symptoms (TIA/stroke). The extensive and
rigorous credentialing process for carotid interventionalists
in CREST may explain these contradictory results.23
The results of two recent meta-analyses lend support to
the superiority of CEA over CAS in symptomatic patients.
According to the first meta-analysis (10 trials; 3,580 pa-
tients), when a subgroup analysis of trials was performed
including only symptomatic patients with a 60% carotid
stenosis, the 30-day risks for stroke (relative risk [RR],
1.62; 95% CI, 1.13-2.31 after CAS use; P  .05) and any
stroke or death (RR, 1.63; 95% CI, 1.18-2.25 after CAS
use; P  .05) were significantly higher in CAS patients,
“making it a suboptimal choice for symptomatic patients
with moderate to severe stenosis.”1 In the second meta-
analysis,2 when considering only previously symptomatic
patients, CAS was associated with a higher incidence of
stroke and death within 30 days (54 of 1011 vs 90 of 1032
events for CEA vs CAS, respectively; RR, 0.53; 95% CI,
0.30-0.95; P  .003).
A retrospective study including 3,179 CAS procedures
performed at four European high-volume carotid centers
validated CAS as a durable procedure for stroke preven-
tion.24 At 5 years, freedom from mortality, stroke-related
death, ipsilateral fatal/major stroke, and any stroke rate
were 82%, 93.5%, 93.3%, and 91.9%, respectively.24 Free-
dom from restenosis at 1, 3, and 5 years was 98.4%, 96.1%,
and 94%, respectively. Nevertheless, the presence of neuro-
logical symptoms before CAS was the only predictor for
neurological complications postprocedurally (HR, 1.38;
95% CI 1.05-1.82; P  .02).24 Similarly, in the report of
the Vascular Registry of the Society for Vascular Surgery
(6,403 procedures; 3,259 CEA patients; 2,763 CAS pa-
tients), a higher 30-day incidence of death/stroke/MI was
demonstrated for symptomatic patients undergoing CAS
compared with CEA (7.13% vs 3.75%, respectively).25 Al-
though patients undergoing CAS had a higher incidence of
preprocedural TIA or stroke episodes (49.2% vs 42.4%, for
CAS vs CEA, respectively; P .001), better outcomes were
still demonstrated for CEA compared with CAS after riskadjustment for factors found to be significant confounders
in outcomes (ie, age, history of stroke, diabetes, and Amer-
ican Society of Anesthesiologists grade; adjusted OR,
1.965 for CAS vs CEA; P  .001).25
A survey in the United States of all carotid revascular-
ization procedures performed in 2005 (135,701 CEA and
CAS procedures; CEAs: 91%, CAS procedures: 9%) showed
that CAS was associated with both increased postoperative
stroke (1.8% vs 1.1%, respectively; OR, 1.7; 95% CI, 1.2-
2.3; P  .05), as well as overall mortality rates (1.1% vs
0.57%, respectively; OR, 1.5; 95% CI, 0.96-2.5; P  .05),
compared with CEA.26 More importantly, the mortality
difference increased considerably in patients with symp-
tomatic disease (4.6% vs 1.4%, for CAS vs CEA, respec-
tively; P .05).26 The same group showed that stroke and
mortality rates did not differ between vascular surgeons and
nonvascular surgeons (interventional cardiologists and in-
terventional radiologists).27 In the report of two large CAS
studies on patients at high risk for surgery, Emboshield and
Xact Post Approval Carotid Stent Trial (EXACT; n 
2,145 patients; 9.9% symptomatic [TIA, amaurosis fugax,
or stroke episode180 days preprocedurally]) and Carotid
ACCULINK/ACCUNET Post Approval Trial to Uncover
Rare Events (CAPTURE 2; n  4,175 patients; 13.1%
symptomatic), the 30-day combined endpoint of death and
stroke was 6.4% (95% CI, 4.8%-8.4%) for the combined
symptomatic population, while it was 50% lower for the
combined asymptomatic population (3.2%; 95% CI, 2.8%-
3.7%).28 Finally, a recent systematic review (n  206 stud-
ies; 54,713 patients) concluded that symptomatic patients
undergoing CAS were about twice as likely to suffer a
perioperative stroke episode/death compared with asymp-
tomatic individuals (30-day risk [95% CI] of stroke/death:
7.6% [3.6-9.1] vs 3.3% [2.6-4.1], respectively).29
DISCUSSION
To determine what may influence poor CAS outcomes,
it is appropriate to examine the mechanisms accounting for
the inferior results reported to date for CAS compared with
CEA in symptomatic patients so that measures to offset
these mechanisms can be used maximally in the future.
Differences in carotid plaque morphology: the
“unstable” plaque
The carotid plaques of equally stenotic symptomatic
and asymptomatic carotid artery lesions vary considerably
in morphology and structure.30,31 Downstream of a high-
grade internal carotid artery stenosis, cerebral microemboli
occur, which are detectable with transcranial Doppler ul-
trasonography.32,33 The frequency of ultrasonographi-
cally-detected (although not always clinically relevant) mi-
croembolic events is greater in patients with recent
neurological symptoms compared with patients having
similarly severe asymptomatic stenosis.32,33 These observa-
tions lead to the “unstable plaque” theory.30,31 A detailed
discussion of the “unstable plaque” concept is provided
elsewhere.30,31 Briefly, there are broadly two types of ca-
rotid plaque: one is stable and unlikely to produce symp-
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essarily more stenotic) is unstable and at a higher risk of
producing symptomatic or asymptomatic embolization. A
thinner or ulcerated fibrous cap with an increased degree of
inflammation (ie, a greater number of macrophage and T
lymphocytes) overlying a core of lipid and necrotic debris
are prominent characteristics of the “unstable” symptom-
atic plaque. Such plaques are associated with an increased
risk of rupture and neurological symptoms.30-33
Concerns about the safety and efficacy of CAS in treat-
ing unstable plaques were raised in an earlier commen-
tary.34 Maneuvering CAS guidewires and catheters in a
stenotic carotid artery with an “unstable” plaque may dis-
lodge atherosclerotic material and cause thromboembolism
to the cerebral circulation, resulting in TIA or stroke.34 A
randomized study subsequently compared the number of
microemboli detected with transcranial Doppler scan dur-
ing CAS vs CEA.35 A considerably higher number of
microembolic signals were demonstrated for CAS com-
pared with CEA (mean, 202; range, 18-426 signals vs
mean, 52; range, 0-269 signals for CAS vs CEA, respec-
tively; P  .001).35 The higher incidence of microemboli
after CAS compared with CEA was verified in other reports,
as well.36,37 A recent systematic review (n  32 studies;
1,363 CAS and 754 CEA procedures) also showed that the
incidence of new embolic lesions detected by diffusion-
weighted MRI is considerably higher after CAS than after
CEA (37% vs 10%, respectively; P .01).38 By performing
a meta-analysis including those single-center studies that
directly compared the incidence of new diffusion-weighted
MRI embolic lesions after the two procedures, a greater-
than-six-fold-higher incidence of new embolic lesions was
demonstrated after CAS compared with CEA (OR, 6.1;
95% CI, 4.19-8.87; P .01).38 Therefore, unstable carotid
plaques may be associated with higher embolization rates
during CAS compared with CEA.35-38
Embolic events during CAS vs CEA: use of EPDs.
As CAS is associated with a higher incidence of microem-
boli compared with CEA,35-38 several EPDs were intro-
duced in an attempt to reduce the number of embolic
events during CAS. EPDs successfully reduce39,40 (but do
not eliminate)41,42 the number of embolic particles. A
systematic review evaluating the efficacy of EPDs in pre-
venting thromboembolic complications during CAS dem-
onstrated a considerably lower 30-day combined stroke
and death rate in patients treated with EPDs compared with
patients treated without cerebral protection (16 events in
896 procedures vs 140 events in 2,537 procedures, or 1.8%
vs 5.5%, respectively; P  .001).43 There was a three-fold
increased risk of any stroke or death and a greater-than-six-
fold increase of minor stroke within 30 days if CAS was
performed without vs with EPDs.43 More importantly, a
greater-than-six-fold higher 30-day combined stroke and
death rate was demonstrated without the use of EPDs in
symptomatic compared with asymptomatic patients (6.4%
vs 1%, respectively; P  .01).43
A retrospective matched case-control study (301 CAS
[118 symptomatic patients] and 301 CEA procedures [120symptomatic patients]) showed a considerably higher risk
of periprocedural stroke for CAS compared with CEA
(7.9% vs 2.3%; OR, 5.2; 95% CI, 1.7-18; P .001), despite
the use of EPDs in all CAS patients.44 There was, however,
a decreasing trend in 30-day neurological event rates for the
last 201 CAS matched cases, and the difference with CEA
was no longer significant (5.4% vs 1.9%, for CAS vs CEA,
respectively; OR, 2.8; 95% CI, 0.8-10.2; P .1).44 Finally,
EPDs cannot prevent emboli occurring after the removal of
the device. This is important since many neurological
events occur in the 24 hours following completion of the
procedure.14 Finally, distal filters incur the additional risk
of embolization at the time of crossing of the lesion.
Whether the detection of microembolic ultrasonic sig-
nals during CAS or CEA using transcranial Doppler ultra-
sound correlates with the development of ipsilateral focal
cerebral ischemia remains the subject of debate.45,46 A
recent study, however, provided evidence that detection of
solid and gaseous microemboli during CAS and CEA cor-
relates with the development of procedure-related ipsilat-
eral ischemic strokes (solid: P  .027; gaseous: P  .037)
or new ipsilateral diffusion-weighted cerebral MRI lesions
(solid: P  .043; gaseous: P  .026).47 Patients undergo-
ing CAS had more solid (P .001) and gaseous (P .001)
emboli and more new ipsilateral ischemic strokes (P 
.033) compared with CEA patients. More importantly,
echolucent plaques (P  .02) and the presence of prepro-
cedural diffusion-weighted cerebral MRI ischemic lesions
were associated with an increased number of solid emboli
(P  .002).47 Finally, the recently published results of the
ICSS substudy revealing a greatly increased risk of new
lesions after CAS compared with CEA support the need for
improved EPDs and perhaps the use of microfilm-covered
stents.22 Since CAS is associated with the generation of
more microemboli compared with CEA,35-38 this is further
evidence that symptomatic patients should not be treated
by CAS unless means are introduced to render symptomatic
plaques more stable.
Possible options to improve CAS outcomes
1. Modification of vascular risk factors — plaque
stabilization. Several risk factors for the development of
symptomatic carotid artery stenosis and, thus, an increased
stroke risk, have been identified, namely hypertension,
hypercholesterolemia/hyperlipidemia, diabetes mellitus,
smoking, obesity, and physical inactivity.48 Since CAS does
not eliminate the actual cause of carotid stenosis (it merely
displaces the carotid artery atherosclerotic plaque), it
should be expected that maintenance of these risk factors
may be associated with a greater risk of developing recur-
rent carotid stenosis. Thus, modification of the risk factor
profile (eg, weight loss, use of antihypertensive, antiplate-
let, and lipid-lowering medication, optimal glucose man-
agement, and adoption of exercise) may decrease the odds
of developing symptomatic carotid artery disease.48
Since unstable carotid plaques are lipid-rich, a possi-
ble option to improve stroke rates before, during, and
after CAS procedures may be aggressive pre- and post-
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strated that routine statin use significantly reduces the risk
of stroke.49-51 Statins also reduce the incidence of periop-
erative cardiovascular and cerebrovascular events in patients
undergoing CEA.52,53 Although the exact mechanism is
not known, statins exert these effects independent of their
lipid-lowering action via anti-inflammatory, plaque stabili-
zation, and neuroprotective pathways.52-54 Statins are an
essential component in the management of carotid artery
disease.55 In a retrospective review of all CEAs in a large
center (n  1,566 procedures), preoperative statin use was
associated with a reduction in perioperative strokes (1.2% vs
4.5%, respectively; P  .01), TIAs (1.5% vs 3.6%, respec-
tively; P  .01), and all-cause mortality (0.3% vs 2.1%,
respectively; P  .01) when compared with patients not
receiving statins.52 Statin use was independently associated
with a greater-than-three-fold reduction in the odds of
stroke (1.2% vs 4.5%, for statin users vs nonusers, respec-
tively; OR, 0.29; 95% CI, 0.14-0.61; P  .001) and a
7-fold reduction in the odds of death (0.3% vs 2.1%, for
statin users vs nonusers, respectively; OR, 0.14; 95% CI,
0.03-0.62; P  .009).52 In another study on patients
undergoing CEA, statins were associated with better out-
comes (reduced in-hospital mortality and in-hospital
stroke/death rates) in symptomatic but not in asymptom-
atic individuals.56 Similar anti-inflammatory and plaque-
stabilizing effects of statin use on symptomatic patients
undergoing CAS may be suspected; these effects may im-
prove CAS results.
Assuming that statins stabilize carotid plaques,52-55
aggressive pre- and periprocedural statin administration
could decrease emboli generated during manipulation of
wires and catheters during CAS procedures. Taken to-
gether with the statin-induced decrease in the incidence of
adverse events,52,53 the use of aggressive statin treatment
before, during, and after CAS in symptomatic patients may
improve CAS outcomes. This is supported by findings from
studies on coronary stenting that suggest that routine statin
use following coronary stenting is associated with reduced
recurrent coronary stenosis and improved major adverse
cardiovascular and mortality rates.57,58 Verification of these
encouraging results in CAS patients will further support
routine statin use in these individuals as well. So far, only a
retrospective report has investigated the effect of preproce-
dural statin use on the incidence of cardiovascular events
after CAS.59 This study compared the effect of preproce-
dural statin treatment between 53 patients with vs 127
patients without preprocedural statin treatment.59 The
overall 30-day MI rate was 1% (2 of 180 patients), the
minor stroke rate was 9% (16 of 180 patients), the major
stroke rate was 0.5% (1 of 180 patients), and the death rate
was 1% (2 of 180 patients). CAS patients receiving statin
therapy preprocedurally had a lower incidence of cardiovas-
cular events (composite of stroke, MI, and death within 30
days after CAS) compared with CAS patients not receiving
statins prior to the procedure (2 of 53 vs 19 of 127, or 4%
vs 15%, for statin users vs nonusers, respectively; P 
.05).59 Although a “magical” effect of statins should not besupported, these data suggest that routine statin treatment
may be beneficial for patients undergoing CAS.
2. Better patient selection. Better patient selection is
mandatory to improve CAS outcomes.60 Certain high-risk
patients, including those75 years, those with unfavorable
aortic arch or carotid anatomy, and those with unfavorable
lesion characteristics (eg, free-floating thrombus, heavy
circumferential calcification, long string-like lesions)
should probably not undergo CAS. In contrast, patients
with high carotid lesions, restenosis after prior CEA, and
previous neck irradiation or infection will likely benefit
more from CAS than CEA.60
An in-depth review on the identification of clinical and
angiographic features associated with increased procedural
risk after CAS indicated that age 80 years, decreased
cerebral reserve, dementia, prior (remote) stroke, multiple
lacunar infarcts, and intracranial macroangiopathy are clin-
ical features associated with inferior outcomes after CAS.61
Additionally, excessive vascular tortuosity (defined as 2
bend points 900, within 5 cm of the lesion) and heavy
concentric calcification increase the difficulty of access to
the lesion and are important predictors of CAS complica-
tions.61 A higher risk for periprocedural complications for
octogenarians undergoing CAS compared with younger
individuals was also suggested by others.62,63 A higher
incidence of unfavorable anatomy associated with age80
years may explain the poor results of CAS for these pa-
tients.64 Furthermore, the type of aortic arch morphology
(“simple” vs “bovine”), the presence of atherosclerotic arch
lesions (5 mm vs5 mm or with mobile debris), and the
degree of tortuosity may account for a higher number of
embolic brain lesions following CAS.65 Finally, the pres-
ence of certain angiographic carotid lesion characteristics
(ie, lesion length 15 mm and ostial involvement) is asso-
ciated with increased 30-day stroke rates after CAS.66
3. Improved CAS skills/techniques. A possible ex-
planation for the inferior results reported to date for CAS
may be associated with operator inexperience and lack of
standardization of the technique. This certainly applies to a
new treatment method such as CAS when it is compared to
CEA, which has been well-established and refined for 50
years. In support of this, a report presenting an analysis of
the periprocedural complications of CAS underlined the
importance of appropriate and considerable experience be-
fore undertaking systematic use of CAS.67 Similarly, in the
Pro-CAS registry, the risk of stroke after CAS decreased
with center experience (5.9% vs 3.0%, for the first 50
vs 150 interventions, respectively; OR, 1.77; 95% CI,
1.1-2.8; P  .017).15 A similar association was demons-
trated with patient volume (stroke risk: 2.9% vs 4.6%, for
physicians/centers performing50 vs50 interventions/
year; P  .0014). Finally, a decrease in periprocedural
stroke risk was shown with accumulating experience and
evolving CAS techniques (6.1% vs 3.0% for the periods July
1, 1999-June 30, 2000 vs July 1, 2004-June 30, 2005; P
.0294).15 This may result from two factors: increased tech-
nical skill and better patient selection, both of which may
come with greater experience. The recently reported
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credentialing of carotid interventionalists and appropriate
experience.3,23 In CREST,3,23 approval of carotid inter-
ventionalists to participate in the trial was based on ade-
quate experience (defined as30 CAS procedures with low
event rates), use of proper standard CAS technique, or an
adequate number of submitted procedures (15-30 cases
[median, 29] with low event rates), plus appropriate inter-
ventional skills using the correct standard technique.23 In
contrast, in ICSS, a minimum of 10 CAS procedures was
required for participation in the trial,20 whereas in the
Endarterectomy Versus Angioplasty in Patients with Symp-
tomatic Severe Carotid Stenosis (EVA-3S) trial,14,16 partic-
ipating interventional physicians should have performed at
least 12 CAS procedures. Unlike CREST,3,23 the inclusion
of inexperienced operators and lack of uniform use of EPDs
in EVA-3S14,16 and ICSS20 may limit the values of these
studies. Therefore, it may be expected that future trials
comparing CAS with CEA for the management of symp-
tomatic carotid artery stenosis will be designed better and
may produce better results for CAS.68
4. Improved technology for CAS — better EPDs
(flow reversal and proximal occlusion) and better stents
(membrane-covered, ultra-closed cell, and biodegraga-
ble). Several issues may improve CAS outcomes, such as
the introduction of new and better stents. An ex vivo study
showed that use of a polyurethane membrane-covered
stent resulted in lower cerebral embolization rates.69
Membrane-covered stents also have the potential to reduce
the incidence of late embolization, that is, after the removal
of the EPD.70 Furthermore, proximal EPDs (such as the
Mo.Ma flow interruption device [Invatec, Roncadelle,
Italy]71 or the Parodi flow reversal Anti-Emboli System
[W.L. Gore, Flagstaff, AZ])72 offer the advantage of cere-
bral protection during most of the procedure.
In the Mo.Ma trial,71 a new technique was compared
with the standard technique. The new technique included
several technical tips and modifications, such as the engage-
ment of the guidewire’s floppy tip through the carotid
lesion while cerebral blood follow was maintained, a slow
release postdilation (1 Atm/2 sec), a quicker manual aspi-
ration procedure following postdilation, a redirection of
blood flow into the external carotid artery with the postdi-
lation balloon inflated in the internal carotid artery, and a
further manual aspiration and subsequent release of the
Mo.Ma system. The application of this novel technique had
less neurological complications compared with patients
treated with the standard technique (1.1% vs 3.7%, respec-
tively).71 The multicenter ProximAl PRotection with the
Mo.Ma Device DUring CaRotid Stenting (ARMOUR)
trial evaluated the 30-day safety and effectiveness of the
Mo.Ma proximal cerebral protection device in high-
surgical-risk patients undergoing CAS.73 The 30-day major
adverse cardiac and cerebrovascular event rate was as low as
2.7% (95% CI, 1.0%-5.8%), with a 30-day major stroke rate
of only 0.9%. Importantly, no symptomatic patient suffered
a stroke during this trial.73 Finally, the GORE EMbolic
Protection with REverse Flow (EMPiRE) Study demon-strated the safety and efficacy of the GORE Flow Reversal
System for neuroprotection during CAS.74 The GORE
Flow Reversal System provides neuroprotection by revers-
ing the blood flow at the carotid stenosis, thereby directing
embolic particles away from the brain. The 30-day death
and any stroke rate was 2.9%, which is considerably lower
compared with other EPD trials. This study also showed
encouraging results in symptomatic patients demonstrating
combined death, stroke, and MI rates of 3.8%.74 These
results, pointing out the potential benefits of proximal
occlusion/flow reversal systems in symptomatic patients,
require further evaluation.
Finally, other technological advances for CAS include
better filters (eg, Fibernet,75 Emboshield,28 etc.), lower
profile, and improved ways to cannulate arch vessels with
end-manipulateable tipped catheters. Some technical fac-
tors that may also improve CAS outcomes include minimiz-
ing manipulation, poststenting balloon dilatation, and filter
dwell time, as well as accepting a less-than-perfect result in
terms of luminal restoration. As CAS technology and these
technical improvements are introduced and used in trials,
CAS results are expected to improve.68
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